Advanced Filters
noise

Staten Island, New York Clinical Trials

A listing of Staten Island, New York clinical trials actively recruiting patient volunteers.

Found 1,208 clinical trials

RevCore for In Stent Thrombosis

The purpose of this research is to collect information about how the RevCore Thrombectomy Catheter works to treat stent blockages.

18 years of age All Phase N/A

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study drug adherence, and optimize …

45 years of age All Phase 0

Pilot Study on The Effectiveness of Relative Motion Orthosis in Finger Motion

The purpose of this feasibility pilot study is to determine the effectiveness of Relative Motion Orthosis (RMO) in regaining finger range of motion compared to standard care in patients diagnosed with Proximal Interphalangeal (PIP) stiffness with an extension lag secondary to finger injury. Participants will be enrolled and randomized into …

18 - 80 years of age All Phase N/A
S Shannen Belotte

BioHealx® Anal Fistula Device Post Market Surveillance Study

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).

18 - 75 years of age All Phase N/A

Transplanting Lungs From Uncontrolled Donation After Circulatory Death

The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and …

18 years of age All Phase N/A
P Paul Corn, MD

Comprehensive Assessment of Cancer Theranostic Response

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected …

18 years of age Male Phase N/A
M Mackenzie Doerstling, MPH

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: Long Covid (LC) Post-treatment Lyme disease syndrome (PTLDS) Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

18 years of age All Phase 1/2

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

18 - 65 years of age All Phase 3
G Garrett Gianneschi, DO

Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4

The primary purpose of this study is to serve as a pilot study of the EFIL device treatment feasibility of IVH grades 3,4 to guide development of a larger trial. Primary outcomes will assess the following: safety of intervention, recruitment and consent process, acceptability of intervention by parents, retention rates, …

- 1 years of age All Phase N/A

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. Pemvidutide: 2.4 mg SC once weekly Placebo: Placebo SC once weekly

18 - 75 years of age All Phase 2

Simplify language using AI